Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) has announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of US$40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the US.
Latham represented Coherus in the transaction with a corporate deal team led by Bay Area partners Jekkie Kim, Ben Potter, and Josh Dubofsky, with associates Danny Nordstrom and Alex Bogdon. Advice was also provided on healthcare and life sciences matters by associates Fiona Gillan, Mizuna Sekine, and Patrick Chew; on tax matters by Bay Area partner Grace Lee, with associate Dennis Poehland; on data privacy matters by Bay Area partner Heather Deixler; and on securities matters by Bay Area partner Philip Stoup, with associate Tess Bloom.
